Knowledge Intensive Services
Antimicrobial Resistance Policy Solutions
It is difficult to imagine someone who hasn’t called on antibiotics to help them through an infection or protect them during a surgery. Thanks to developments over the last 150 years, once life-threatening bacterial encounters have been relegated to minor inconveniences. Or have they? T...
Good business coaching is so powerful that if it were a drug it would be illegal
Chris Dunn writes..It’s use it or lose it time! But don't just spend your end-of-year budget, invest it for maximum return. And there's no better return than investing in executive coaching or business mentoring. ...
How well equipped are you to lead change?
Chris Dunn writes...Leading change is one of the most challenging aspects of leadership. This is not only because the pace of change is accelerating but also because so much seems to be changing all at the same time. So, where do leaders and senior managers get the right support to hel...
3 Steps for cell & gene therapy medical affairs teams to provide strategic value
A phrase often recited within the pharmaceutical and biotechnology industries in recent years is that medical affairs is the third strategic pillar of success, along with R&D and commercial. Ongoing advancements in the cell and gene therapy sector have further highlighted the critic...
The Paradigm Shift: Navigating the emergence of value-based contracts for future gene therapies
Value-based contracting (VBC) has been difficult to execute in the pharmaceutical arena, especially in the gene therapy space. This has been driven by several factors, including the lack of long-term data, the imbalance of upside and downside risk between manufacturers and payers, and d...
A longitudinal perspective on innovation
There is growing interest in the innovation process in the biopharmaceutical industry, with particular public scrutiny around the composition of research and development (R&D) spending and the role of intellectual property. This process is commonly characterized as involving a mixtu...
Oncology vaccines: Are they positioned for PMA success?
With combinations taking center stage following the initial influx of immune checkpoint inhibitor monotherapies, the authors look ahead to the potential of mRNA vaccines in oncology and describe the pricing and market access opportunities and challenges that may await current and future...
The burden of non-specific pain disorder in US women
Based on existing evidence on the delay, lack of recognition, and burden of pain conditions commonly afflicting women (specifically endometriosis, PCOS, fibromyalgia, IBS or migraines), CRA sought to understand how being diagnosed with these conditions impacts women’s mental health and ...
The longitudinal history of medicines innovation: Part two
The second of a two-part article, CRA’s Life Sciences Practice team, along with experts at The Janssen Pharmaceutical Companies of Johnson & Johnson, recently conducted a landscape review of how complex pharmaceutical innovation happens in practice, leveraging three therapy area cas...
The longitudinal history of medicines innovation: Part One
This article is originally published in PharmaPhorum. As we move forwards in public discussions on pharmaceutical innovation and its value to patients and society, it is helpful to ground conversations in a solid understanding of how medicines development occurs. ...